<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Two common mutations in the exon IIIa of fibroblast growth factor receptor 2 account for majority of the cases of <z:e sem="disease" ids="C0001193" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Apert syndrome</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>They can be analyzed by amplifying the segment followed by testing for the abolition of restriction sites </plain></SENT>
<SENT sid="2" pm="."><plain>We evaluated two children with typical features of <z:e sem="disease" ids="C0001193" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Apert syndrome</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>A segment of FGFR2 exon IIIa was amplified by polymerase chain reaction </plain></SENT>
<SENT sid="4" pm="."><plain>Restriction fragment length polymorphism was analyzed using enzymes MboI and BglI respectively for S252W and P253R mutations </plain></SENT>
<SENT sid="5" pm="."><plain>The DNA segment was sequenced using ABI 310 automated DNA fragment analyzer </plain></SENT>
<SENT sid="6" pm="."><plain>Both the patients showed S252W mutations </plain></SENT>
<SENT sid="7" pm="."><plain>DNA sequencing confirmed the results of the restriction fragment length polymorphism </plain></SENT>
<SENT sid="8" pm="."><plain>Our study is the first report from Indian subcontinent to show the prevalence of S252W mutation among <z:e sem="disease" ids="C0001193" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Apert syndrome</z:e> patients from Indian origin </plain></SENT>
</text></document>